Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.
Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TXA | Tranexamic acid was administered to the participants at a dose of 1.0 g during the induction of anaesthesia and immediately after the operation. |
| |
| Non-TXA | Tranexamic acid were not administred to the participants . |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tranexamic acid injection | Drug | Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants who require a blood transfusion. | Need of blood transfusion | During Hospitalization (up to day 10) |
| Measure | Description | Time Frame |
|---|---|---|
| Estimeted blood lost after surgery. | Gross total blood loss was estimated utilizing the formula PBV × (Hctpre- Hctpost)/Hcta | During Hospitalization (up to day 3) |
| Number of participants with embolic complication. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Investigetor analysed a group of paticipants who underwent surgery for metastatic tumours of the proximal femur using modular prostheses between 2017 and 2021.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SzSPOO Brzozów | Brzozów | Podkarpackie Voivodeship | 36-200 | Poland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21439633 | Result | CRASH-2 collaborators; Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 Mar 26;377(9771):1096-101, 1101.e1-2. doi: 10.1016/S0140-6736(11)60278-X. | |
| 41180854 |
Not provided
Not provided
The datasets used and/or analysed during the current study are available from the corresponding investigator on reasonable request.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D009369 | Neoplasms |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D014148 | Tranexamic Acid |
| ID | Term |
|---|---|
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Yes or No
| During Hospitalization (up to day 10) |
| Derived |
| Biega P, Guzik G. Tranexamic Acid Reduces Transfusion Rates After Modular Hemiarthroplasty for Pathological Femoral Fractures: A Retrospective Study. Adv Orthop. 2025 Oct 30;2025:3173784. doi: 10.1155/aort/3173784. eCollection 2025. |